Fulvestrant trials for Metastatic Breast Cancer

All Fulvestrant trials · All Metastatic Breast Cancer trials

Phase breakdown

Recruiting trials studying Fulvestrant for Metastatic Breast Cancer

• A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
  NCT03424005 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
  NCT06110793 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations
• A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
  NCT07347600 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
  NCT05524584 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
  NCT06756932 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 14 locations
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
  NCT06120283 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 62 locations
• First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
  NCT05216432 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 37 locations
• Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
  NCT04263298 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: Female · 13 locations
• Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
  NCT05720260 · Phase: Phase 2 · Ages: 20 Years and older · Sex: Female · 1 location
• Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
  NCT06625775 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 88 locations
• Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
  NCT06784193 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 8 locations
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
  NCT06982521 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 231 locations
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
  NCT06409390 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location

Common questions

How many trials study Fulvestrant for Metastatic Breast Cancer?

14 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.